» Articles » PMID: 39796598

High-Intensity Interval Training Reduces Liver Enzyme Levels and Improves MASLD-Related Biomarkers in Overweight/Obese Girls

Overview
Journal Nutrients
Date 2025 Jan 11
PMID 39796598
Authors
Affiliations
Soon will be listed here.
Abstract

Background/objectives: Despite the abundant body of evidence linking high-intensity interval training (HIIT) to cardiometabolic markers, little is known about how HIIT affects liver enzymes, particularly in obese adolescents. This study aimed to investigate the effects of HIIT on metabolic dysfunction-associated steatotic liver disease (MASLD)-related biomarkers in overweight/obese adolescent girls.

Methods: Thirty-three overweight/obese adolescent girls (age, 17.0 ± 1.15 yr.; body mass index, 33.3 ± 4.77 kg/m) were randomly assigned to HIIT ( = 17) or control ( = 16) groups. The HIIT group participated in a nine-week HIIT program (three times weekly) without caloric restriction. Maximal aerobic speed, body composition indexes, blood pressure, MASLD-related biomarkers [liver enzymes (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), plasma lipids, uric acid, platelet count, and homeostasis model assessment index for insulin-resistance (HOMA-IR)] were examined at baseline and after the intervention.

Results: Significant "time × group" interactions were found for body composition indexes, systolic blood pressure, maximal aerobic speed, liver enzymes ALT and AST, plasma lipids, glucose, and HOMA-IR. The HIIT program resulted in an increase in maximal aerobic speed ( = 0.035) and a decrease in body composition and plasma lipids ( < 0.01), systolic blood pressure ( = 0.011), ALT ( = 0.013), AST ( = 0.012), and HOMA-IR ( = 0.01), but no significant changes in uric acid and platelet count. None of these markers changed in the control group.

Conclusions: HIIT resulted in an improvement in MASLD-related biomarkers. HIIT could be an effective exercise therapy to prevent and reverse MASLD in adolescents with obesity.

References
1.
Watt M, Miotto P, De Nardo W, Montgomery M . The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019; 40(5):1367-1393. DOI: 10.1210/er.2019-00034. View

2.
Ahmadizad S, El-Sayed M . The effects of graded resistance exercise on platelet aggregation and activation. Med Sci Sports Exerc. 2003; 35(6):1026-32. DOI: 10.1249/01.MSS.0000069406.54766.C6. View

3.
Wong V, Wong G, Chan R, Shu S, Cheung B, Li L . Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018; 69(6):1349-1356. DOI: 10.1016/j.jhep.2018.08.011. View

4.
Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh B . Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol. 2024; 12:1433857. PMC: 11289778. DOI: 10.3389/fcell.2024.1433857. View

5.
Jiang Q, Mao R, Wu J, Chang L, Zhu H, Zhang G . Platelet activation during chronic hepatitis B infection exacerbates liver inflammation and promotes fibrosis. J Med Virol. 2019; 92(12):3319-3326. DOI: 10.1002/jmv.25641. View